251 related articles for article (PubMed ID: 27074261)
1. Highlights from the 2015 North American Cystic Fibrosis Conference.
Zemanick ET; Ong T; Daines CL; Dellon EP; Muhlebach MS; Esther CR
Pediatr Pulmonol; 2016 Jun; 51(6):650-7. PubMed ID: 27074261
[TBL] [Abstract][Full Text] [Related]
2. Highlights from the 2016 North American Cystic Fibrosis Conference.
Zemanick ET; Daines CL; Dellon EP; Esther CR; Kinghorn B; Ong T; Muhlebach MS
Pediatr Pulmonol; 2017 Aug; 52(8):1103-1110. PubMed ID: 28696526
[TBL] [Abstract][Full Text] [Related]
3. Highlights from the 2017 North American Cystic Fibrosis Conference.
Martiniano SL; Toprak D; Ong T; Zemanick ET; Daines CL; Muhlebach MS; Esther CR; Dellon EP
Pediatr Pulmonol; 2018 Jul; 53(7):979-986. PubMed ID: 29660839
[TBL] [Abstract][Full Text] [Related]
4. Highlights from the 2018 North American cystic fibrosis conference.
Martiniano SL; Daines CL; Dellon EP; Esther CR; Muhlebach MS; Ong T; Rabinowitz EC; Toprak D; Zemanick ET
Pediatr Pulmonol; 2019 Jul; 54(7):941-948. PubMed ID: 31091021
[TBL] [Abstract][Full Text] [Related]
5. Highlights from the 2019 North American Cystic Fibrosis Conference.
Hoppe JE; Guimbellot J; Martiniano SL; Toprak D; Davis C; Daines CL; Muhlebach MS; Esther CR; Dellon EP
Pediatr Pulmonol; 2020 Sep; 55(9):2225-2232. PubMed ID: 32573948
[TBL] [Abstract][Full Text] [Related]
6. What did we learn from the North American Cystic Fibrosis Conference?
Bilton D
J R Soc Med; 2008 Jul; 101 Suppl 1(Suppl 1):S6-9. PubMed ID: 18607012
[No Abstract] [Full Text] [Related]
7. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
[TBL] [Abstract][Full Text] [Related]
8. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee T; Southern KW
Cochrane Database Syst Rev; 2007 Apr; (2):CD005599. PubMed ID: 17443603
[TBL] [Abstract][Full Text] [Related]
9. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW
Cochrane Database Syst Rev; 2013 Nov; (11):CD005599. PubMed ID: 24282073
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Pulmonology year in review 2015: Part 4.
Savant AP; McColley SA
Pediatr Pulmonol; 2016 Jul; 51(7):754-65. PubMed ID: 27171478
[TBL] [Abstract][Full Text] [Related]
11. Highlights of the 28(th) North American Cystic Fibrosis Conference 2014.
Nwokoro CE
Paediatr Respir Rev; 2015 Oct; 16 Suppl 1():12-4. PubMed ID: 26410289
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
13. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW
Cochrane Database Syst Rev; 2012 Oct; 10():CD005599. PubMed ID: 23076917
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
15. Differences in gene mutations between Chinese and Caucasian cystic fibrosis patients.
Zheng B; Cao L
Pediatr Pulmonol; 2017 Mar; 52(3):E11-E14. PubMed ID: 27717243
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis - an example of personalized and precision medicine.
Skov M; Hansen CR; Pressler T
APMIS; 2019 May; 127(5):352-360. PubMed ID: 30761610
[TBL] [Abstract][Full Text] [Related]
17. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
18. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
19. Highlights of the North American Cystic Fibrosis Conference 2011.
Pabary R; Thursfield R; Davies JC
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S9-13. PubMed ID: 22688370
[No Abstract] [Full Text] [Related]
20. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
